跳至主要内容
临床试验/ISRCTN12394097
ISRCTN12394097已完成不适用

Safety and efficacy of artemether-lumefantrine therapy for Intermittent Preventive Treatment in pregnancy in Uganda

ICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)0 个研究点目标入组 1,664 人开始时间: 2006年10月5日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
1,664

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

性别
Female

入选标准

  • 1. Pregnant with a gestational age between 20 to 28 weeks
  • 2. Residing within a radius of 20 miles from the hospital
  • 3. Attending AnteNatal Clinic (ANC) and has not yet received regular programme IPTp with SP
  • 4. Attending ANC and last received anti-malarial treatment greater than one month ago
  • 5. Gives informed consent for study participation
  • 6. Able to come for follow-up

排除标准

  • 1. Known allergy to SP or artemether-lumefantrine
  • 2. Previously diagnosed with Glucose-6-phosphate dehydrogenase deficiency
  • 3. Presently ill with a medical condition requiring admission to hospital
  • 4. Known patient with cardiac disease or arrhythmia
  • 5. Intrauterine foetal death in the current pregnancy

研究者

发起方
ICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR)

相似试验

Safety and efficacy of artemether-lumefantrine... | 临床试验